Guy Martin

Plenty of biotech companies claim to be leading a revolution with their approach to disease.

When James Burt, the chief executive of lifecycle management healthcare company Pharmanovia, looks back at the mood in the pharma industry in 2023, he is happy

German firm Tubulis has just announced a 128 million euros ($138.8 million) Series B2 financing.

Marc de Garidel, chief executive of French clinical-stage biotech Abivax (Nasdaq: ABVX), has good reason for his belief in the company’s pioneering lead asset,

Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past qua

It is not every day that an Italian biotech company raises 23 million euros ($24.7 million) in a Series A financing.

Plenty of companies in the pharmaceutical industry talk the talk when it comes to focusing on patients.

Amid a surge in radiopharmaceutical investments, Pentixapharm, a subsidiary of Eckert & Ziegler Group, is set to spin off as an independent company listed on the Frankfurt Stock Exchange. Pentixapharm, based in Würzburg and Berlin, focuses on CXCR4 ligand-based theranostics targeting hematological cancers, solid tumors, and other diseases. Its lead diagnostic, Ga68-PentixaFor, is in Phase III trials for primary aldosteronism, offering a non-invasive alternative to adrenal vein sampling. The company has also received Orphan Drug Designation from the EMA for diagnosing marginal zone lymphoma and is advancing therapeutic programs, including PentixaTher for leukaemias and lymphomas. Pentixapharm recently acquired Glycotope’s target discovery business, expanding its IP portfolio and development pipeline beyond the CXCR4 receptor. CEO Hakim Bouterfa emphasized the favorable side effect profile of therapeutic

At the European Cell and Gene Therapy Summit 2024, confidence in the sector’s maturity and progress was evident, highlighted by Ramin Baghirzade of Charles River Labs. With increased investment, a focus on solid data, and growing interest in areas like ophthalmology and oncology, the industry seeks broader commercial success

Merck has over 25 years in MS care, aiming to support patients throughout their journey, including aging with MS. With an aging MS population, challenges arise due to immunosenescence, comorbidities, and limited treatment data for older adults. Merck is committed to addressing these gaps, sharing real-world data at ECTRIMS 2024